ATOSSA THERAPEUTICS, INC.
ATOSSA THERAPEUTICS, INC. (ATOS): 3 pipeline candidates · ~10 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
10.4 months
D/E 0.24 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for ATOSSA THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$23.4M
Cash
$31.7M
Quarterly Burn
$9.6M
Runway
10.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| -endoxifen | Phase 2 |
| goserelin | Phase 2 |
| z-endoxifen | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$8.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 698,192 | $3.7M |
| ameriprise financial inc | 255,134 | $1.3M |
| blackrock, inc. | 133,169 | $700K |
| renaissance technologies llc | 109,007 | $573K |
| geode capital management, llc | 97,061 | $511K |
| millennium management llc | 66,739 | $351K |
| susquehanna international group, llp | 55,000 | $289K |
| vanguard fiduciary trust co | 52,235 | $275K |
| state street corp | 39,761 | $209K |
| northern trust corp | 19,224 | $101K |
Showing top 10 of 31 institutional holders of ATOSSA THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ATOSSA THERAPEUTICS, INC.'s pipeline?
ATOSSA THERAPEUTICS, INC. (ATOS) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ATOSSA THERAPEUTICS, INC.'s lead drug candidate?
ATOSSA THERAPEUTICS, INC.'s most advanced tracked candidate is -endoxifen (Phase 2) for Breast Neoplasms.
What is ATOSSA THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ATOSSA THERAPEUTICS, INC. has approximately 10.4 months of cash runway.
What is ATOSSA THERAPEUTICS, INC.'s market capitalization?
ATOSSA THERAPEUTICS, INC.'s market capitalization is approximately $23.4M.
Who is the CEO of ATOSSA THERAPEUTICS, INC.?
Dr. Steven C. Quay FCAP, M.D., Ph.D. is the chief executive officer of ATOSSA THERAPEUTICS, INC. (ATOS).
Get the full picture on ATOSSA THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.